Glucotrack, Inc.
No SEC Form 4 filings for $GCTK in the last 30 days.
See all $GCTK insider activity →Glucotrack (GCTK) raised $2M via senior secured convertible notes and warrants, with notes carrying 8% annual interest and maturing in 9 months. Dawson James Securities acted as placement agent for a 7% fee and warrants. The funds were raised through a private placement.
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Reverse Stock Split 1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026 RUTHERFORD, N.J., and LA JOLLA, C.A., October 22, 2026 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
Glucotrack (GCTK) will execute a 1-for-2 reverse stock split on October 26, 2026, to maintain its Nasdaq listing. Outstanding shares will reduce from 2.37M to ~1.18M. Shareholder ownership percentages remain unchanged. The company's biopharmaceutical and diabetes technology focus continues.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning GCTK (Glucotrack, Inc.). Coverage has skewed bearish: 0 bullish, 4 neutral, and 1 bearish.
Recent GCTK coverage spans corporate actions, technology and market movers.
The convertible note issuance may dilute existing shareholders and add debt, likely pressuring the stock lower.
The reverse split reduces share count by half, aiming to lift the share price above $1.00, which may attract institutional investors and stabilize the stock.
The split reduces share count, potentially boosting share price and liquidity, but may cause short-term volatility.
The new warrants increase potential dilution and may pressure the stock until the financing is completed.
The waiver lifts issuance restrictions and creates new warrants that could dilute existing shareholders if exercised.
AlphAI scores every news story that mentions GCTK with an AI model for sentiment and relevance, and aggregates insider trades from Glucotrack, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Glucotrack (GCTK) raised $2M via senior secured convertible notes and warrants, with notes carrying 8% annual interest and maturing in 9 months. Dawson James Securities acted as placement agent for a 7% fee and warrants. The funds were raised through a private placement.
1 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Reverse Stock Split 1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026 RUTHERFORD, N.J., and LA JOLLA, C.A., October 22, 2026 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
2 min readGlucotrack (GCTK) will execute a 1-for-2 reverse stock split on October 26, 2026, to maintain its Nasdaq listing. Outstanding shares will reduce from 2.37M to ~1.18M. Shareholder ownership percentages remain unchanged. The company's biopharmaceutical and diabetes technology focus continues.
1 min readGlucotrack (GCTK) agreed to issue 406,198 new 5-year warrants at $7.50 to certain warrant holders, lifting issuance restrictions and waiving anti-dilution adjustments. The move aims to facilitate near-term financing, pending stockholder approval for share issuance under Nasdaq rules.
1 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On October 13, 2026, Glucotrack, Inc. (the “Company”) entered into a Waiver Agreement (the “Waiver”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per shar
1 min readGlucotrack's subsidiary Lōkahi Therapeutics launched Qare, a health platform for comparing medication experiences, starting with GLP-1 drugs. The app matches users by profile and medication, generating real-world data. Lōkahi aims to expand Qare to other therapeutic categories and believes it may offer long-term value to patients and manufacturers.
2 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. As previously disclosed, on July 14, 2026, Glucotrack, Inc. (the “Company”) entered into a securities purchase agreement as supplemented by a joinder dated August 4, 2026 (the “Purchase Agreement”), with certain investors (th
1 min readGlucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Pricing of $3 Million Public Offering RUTHERFORD, N.J. & LA JOLLA, Calif.: Sept. 24, 2026—(BUSINESS WIRE)—Glucotrack, Inc. (NASDAQ: GCTK) (“Glucotrack” or the “Company”) today announced the pricing of a “best efforts” public offering of 169
1 min readBiotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
3 min readGlucoTrack, Inc. (GCTK) rose 26.64% to $2.5717 after announcing a public offering of 169,388 shares at $2.04 each and warrants for 1,350,220 shares at $2.039 per warrant. The company expects $3.10M in gross proceeds, with the offering expected to close by September 25. Trading volume surged to 45.93M shares.
1 min read
